NCT06409325 Effectiveness of MST Versus ECT for Major Depressive Episode
| NCT ID | NCT06409325 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Mental Health Center |
| Condition | Major Depressive Disorder (MDD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 210 participants in total. It began in 2024-08-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Despite advancements in Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) for Major Depressive Disorder (MDD), there remains a need for further research to replicate clinical outcomes and understand the therapeutic targets of these treatments. This study aims to address these gaps through a double-blinded, randomized, non-inferiority investigation comparing the efficacy, tolerability, cognitive adverse effects, and neurophysiological biomarkers of MST and bilateral ECT in patients with MDD.
Eligibility Criteria
Inclusion Criteria: * Participants must meet the diagnostic criteria for MDD as outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). * Participants must have a baseline score of 18 or higher on the 24-item Hamilton Depression Rating Scale (HDRS-24). * During the trial's treatment period, participants must be using a single antidepressant medication at a stable dose. * Participants must be between the ages of 18 and 65 years. * Informed consent from both parents and legal guardians is required. Exclusion Criteria: * Individuals with current or history of organic brain disorders or neurological disorders will be excluded from the study. * Participants with a Wechsler Abbreviated Scale of Intelligence (WASI) score of less than 70 will be excluded. * Individuals currently taking antiepileptic drugs, benzodiazepines, or other medications that may affect seizure activity will be excluded from the study. * Those with exposure to ECT, modified ECT, MST, transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or other neurostimulation treatments in last 6 months will be excluded. * Individuals with cochlear implants, cardiac pacemakers, implanted devices, or metal in the brain will be excluded from participation. * Pregnant or lactating individuals will be excluded from the study. * Individuals currently participating in another concurrent clinical trial will not be eligible for inclusion. * Participants who refuse to provide informed consent to participate in the trial will be excluded. * Other circumstances deemed unsuitable for participation by researchers will result in exclusion.
Contact & Investigator
TianHong Zhang, Doctor
PRINCIPAL INVESTIGATOR
Shanghai Mental Health Center
Frequently Asked Questions
Who can join the NCT06409325 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Major Depressive Disorder (MDD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06409325 currently recruiting?
Yes, NCT06409325 is actively recruiting participants. Contact the research team at zhang_tianhong@126.com for enrollment information.
Where is the NCT06409325 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06409325 clinical trial?
NCT06409325 is sponsored by Shanghai Mental Health Center. The principal investigator is TianHong Zhang, Doctor at Shanghai Mental Health Center. The trial plans to enroll 210 participants.